Vascular Health and Risk Management

Real-World Evidence in Cardiovascular and Vascular Medicine: From Risk Assessment to Clinical Outcomes

We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the important role of real-world evidence (RWE) studies in cardiovascular and vascular medicine.

While randomized controlled trials remain the gold standard for understanding the efficacy and safety of drugs under highly controlled conditions, real-world evidence (RWE) studies help to reveal a treatment’s true effectiveness in everyday patient populations. Integration of RWE into decision-making processes reflects its growing importance as a supportive tool for both clinicians and patients, but also in shaping broader healthcare decisions and regulatory approvals. RWE also provides complementary insights into treatment safety, disease progression, and long-term clinical outcomes across diverse patient populations and healthcare settings.

The increasing availability of electronic health records, clinical registries, administrative databases, and large-scale population studies offers important opportunities to improve cardiovascular risk assessment, evaluate therapeutic strategies, and inform clinical decision-making.

Given the global importance of RWE in understanding and managing Cardiovascular and Vascular Medicine, the journal Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring real-world evidence in Cardiovascular and Vascular Medicine.

The Collection, led by Editor-In-Chief Professor Mirna Chahine, will be included in Taylor & Francis’ Real-World Evidence Series. Papers published within the series will benefit from additional promotional activities across Taylor & Francis, increasing the discoverability and visibility of your research.

1. Scope and Topics of Interest

The Collection is open to submissions across the broad spectrum of RWE research, with a particular interest in the following areas:

• Hypertension and vascular dysfunction, including blood pressure management, arterial stiffness, and vascular aging.
• Atherosclerotic and vascular diseases, including coronary artery disease, peripheral arterial disease, and clinical outcomes.
• Cardiometabolic risk and cardiovascular prevention, including diabetes, dyslipidemia, obesity, and cardiovascular risk prediction.
• Comparative effectiveness, treatment adherence, pharmacovigilance, and long-term safety of cardiovascular therapies.
• Cardiovascular and vascular interventions, including treatment outcomes and long-term follow-up.
• Health disparities, access to cardiovascular care, and population-based outcomes.

2. Eligible Study Designs and Methodological Considerations

The Collection welcomes submissions employing the following study designs and approaches:

• Pragmatic Clinical Trials evaluating the effectiveness of an intervention in routine, real-world clinical practice.
• Observational cohort studies using real-world data.
• Patient registry studies and analyses of appropriate real-world data sources, including clinical registries, electronic health records, administrative claims databases, population-based surveys, and large-scale research resources (e.g., IQVIA datasets, SEER, NHANES, and UK Biobank), provided the research demonstrates clear cardiovascular or vascular relevance.
• Comparative Effectiveness, Pharmacovigilance and Drug Safety research utilizing Electronic Health Record (EHR) data.
• Integration of RWE with health technology & AI, where results provide actionable clinical insights.

Submissions should demonstrate scientific relevance, originality, clearly described data sources and eligibility criteria, and appropriate analytical methods. Particular attention should be given to potential confounding, selection bias, missing data, and study limitations. Relevant reporting guidelines, including STROBE and RECORD, should be followed where applicable.

All studies must comply with applicable ethical and data-protection requirements, including ethics committee or institutional review board approval or exemption, as appropriate. Studies employing AI or predictive models should additionally demonstrate appropriate model validation and clinically meaningful findings.

3. Submission Information

Submitting authors are eligible for a 20% discount on the Article Publishing charge by reaching out to the Commissioning Editor Catherine Teng. If eligible, the discount code must be applied at the point of submission. The deadline for submissions is the 1 of January 2028.